Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization

pfizer-ends-covid-19-trial-with-95%-efficacy,-to-seek-emergency-use-authorization

Reuters Released at: November 18, 2020 Upgraded at: November 18, 2020 18: 46 Pfizer Inc PFE.N said on Wednesday that last outcomes from the late-stage trial of its COVID-19 vaccine reveal it was 95% reliable, including it had the required two-months of safety information and would use for emergency situation U.S. permission within days. Pfizer […]

Reuters

Released at: November 18, 2020

Upgraded at: November 18, 2020 18: 46

Pfizer Inc PFE.N said on Wednesday that last outcomes from the late-stage trial of its COVID-19 vaccine reveal it was 95% reliable, including it had the required two-months of safety information and would use for emergency situation U.S. permission within days.

Pfizer said on Wednesday there had been 170 cases of the disease in its trial of more 43,000 volunteers, of which 162 were observed in the placebo arm and 8 were in the vaccine group.

” With hundreds of thousands of individuals around the world infected every day, we urgently require to get a safe and effective vaccine to the world,” Pfizer CEO Albert Bourla said in a statement.